35 completed, 18 recruiting, 13 unknown, 12 active not recruiting. 44 Phase 2, 23 Phase 1, 6 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow this condition Literature Review of Adrenocortical Carcinoma trials Research Report on Adrenocortical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma Surgical resection, Preoperative RT - Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC) | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2026-10-26 | 2026-10-21 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-10-26 | 2026-10-21 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-09-18 |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer DS9051b - Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Daiichi Sankyo | 40 | 2025-11-04 | 2026-05-22 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Cemiplimab - Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 31 | 2025-09-18 | 2025-10-06 |
| A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery. Radiation - Radiotherapy, High-risk Localized Adrenocortical Carcinoma | Not applicable | Not yet recruiting | Sun Yat-sen University | 58 | 2025-09-15 | 2025-09-03 |
| Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma Adrenal Cortical Carcinoma | Recruiting | University Hospital, Strasbourg, France | 60 | 2025-06-10 | 2026-01-13 | |
| Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma Camrelizumab, Apatinib, mitotane - Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Recruiting | West China Hospital | 28 | 2025-03-15 | 2025-06-03 |
| Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma Triprolizumab, rodiotherapy - Adrenocortical Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 18 | 2025-03-14 | 2025-04-29 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Dostarlimab, Chemotherapy - Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma | Phase 2 | Recruiting | UNICANCER | 120 | 2024-07-23 | 2025-12-02 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-10-16 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) individualized mRNA neoantigen vaccine (mRNA-0523-L001) - Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | Not applicable | Recruiting | Shanghai Jiao Tong University School of Medicine | 21 | 2024-01-13 | 2026-04-09 |
| Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Ablative Radiotherapy, Pembrolizumab - Adrenocortical Carcinoma, ACC | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2023-09-27 | 2026-04-15 |
| Phase 1 Study of 68Ga-R8760 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection - Adrenocortical Carcinoma | Phase 1 | Terminated | Radionetics Oncology | 11 | 2023-09-11 | 2024-12-09 |
| Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy Adrenal Tumor, Adrenal Disease | Unknown | University Hospital Olomouc | 100 | 2023-09-03 | 2023-09-22 | |
| The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma Adrenocortical Carcinoma | Unknown | Shanghai Jiao Tong University School of Medicine | 50 | 2023-05-01 | 2023-05-06 | |
| A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Mitotane, Pembrolizumab - Adrenocortical Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-03-23 | 2025-06-19 |
Showing 20 of 94. Sign in to see all of them.
Pheochromocytoma (13) · Adrenal Gland Neoplasms (12) · Breast Neoplasms (11) · Carcinoma, Renal Cell (11) · Neoplasms (11) · Carcinoma, Hepatocellular (10) · Sarcoma (10) · Adrenal Cortex Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (9) · Cushing Syndrome (9) · Colonic Neoplasms (8) · Melanoma (8) · Pancreatic Neoplasms (8) · Colorectal Neoplasms (7)
Carcinoma (94) · Endocrine Gland Neoplasms (94) · Neoplasms by Histologic Type (94) · Neoplasms by Site (94) · Neoplasms, Glandular and Epithelial (94) · Adenocarcinoma (93) · Adrenal Cortex Diseases (93) · Endocrine System Diseases (93) · Adrenal Gland Diseases (92) · Adrenal Cortex Neoplasms (85) · Neoplasms (83) · Adrenal Gland Neoplasms (82) · Neoplasms, Germ Cell and Embryonal (30) · Neoplasms, Nerve Tissue (30) · Neuroectodermal Tumors (29)
Mitotane (10) · Cisplatin (9) · pembrolizumab (7) · Doxorubicin (6) · Etoposide (5) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · Specimen Handling (4) · Cytoreduction Surgical Procedures (3) · cabozantinib (3) · relacorilant (3) · Cyclophosphamide (2) · Dichlorodiphenyldichloroethane (2) · Ipilimumab (2) · Radiotherapy (2)
National Cancer Institute (NCI) (18) · University of Wuerzburg (6) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (5) · Children's Oncology Group (4) · Corcept Therapeutics (3) · M.D. Anderson Cancer Center (3) · INSYS Therapeutics Inc (2) · Memorial Sloan Kettering Cancer Center (2) · National Institutes of Health Clinical Center (CC) (2) · Seoul National University Hospital (2) · Shanghai Jiao Tong University School of Medicine (2) · Sun Yat-sen University (2) · University of Turin, Italy (2) · West China Hospital (2) · AbbVie (1)
United States (56) · Germany (14) · Italy (13) · Canada (9) · France (9) · Netherlands (8) · Australia (7) · United Kingdom (6) · China (5) · Poland (4) · South Korea (4) · Spain (4) · Denmark (3) · Sweden (3) · Austria (2)
Martin Fassnacht, MD (7) · Alfredo Berruti, MD (3) · Jaydira Del Rivero, M.D. (3) · Andreas G Moraitis, MD (2) · Jeremy L Davis, M.D. (2) · Jonathan M Hernandez, M.D. (2) · Massimo Terzolo, MD (2) · Nitya Raj, MD (2) · A.F. Muller, MD, PhD (1) · Alex A. Adjei, MD, PhD (1) · Alfredo Berruti (1) · Alfredo Berruti MD (1) · Alfredo Berruti, Prof, MD (1)
PMID 22551107, PMID 16172198, PMID 17554118, PMID 20580485, PMID 22997446, PMID 25559399, PMID 11745214, PMID 11762335, PMID 14985252, PMID 15867769, PMID 16172456, PMID 16580903, PMID 16670169, PMID 16680602, PMID 1675220, PMID 16895957, PMID 18334586, PMID 18491247, PMID 18506026, PMID 18619560, PMID 18764725, PMID 18824557, PMID 19025987, PMID 19223900, PMID 19494162, PMID 19500762, PMID 19851811, PMID 20668036, PMID 21220434, PMID 21246024, PMID 21470991, PMID 21612468, PMID 21718784, PMID 21883349, PMID 22143204, PMID 22156929, PMID 22170717, PMID 22170726, PMID 22189997, PMID 22344233, PMID 22480131, PMID 22837187, PMID 22964741, PMID 23091116, PMID 23150683, PMID 23150691, PMID 23370353, PMID 23470964, PMID 23704714, PMID 23970019
U10CA098543 (4), 2016 (2), N01CM00038 (2), U10CA180886 (2), 2009 (1), 2018 (1), 2025 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62204 (1), N01CM62205 (1), N01CM62207 (1), P30CA015083 (1)